Orpheus is dedicated to the development of a novel class of therapeutics for autoimmune disorders, which currently afflict five percent of the US population. Our core technology, the Pantid®, is designed to specifically neutralize the pathological component of patient antibody responses and destroy destructive immune cells, without affecting the patient's immune system functionality. Consequently, our therapeutics will produce robust responses with minimal adverse effect profiles.
Orpheus is dedicated to the development of the PantId®, which is a novel, modular platform therapeutic for the treatment of autoimmune diseases. PantIds® specifically target the cells that cause autoimmune diseases, without affecting the entire immune system.
Unlike conventional autoimmune disease therapies that inhibit the entire immune system, PantIds® do not affect T or B cells outside the autoimmune compartment being specifically targeted. As a result, there is no increased risk of infection, cancer, or other adverse effects associated with generalized immunosuppressants.
- Unlike existing therapeutics, Orpheus' PantIds® target the cause of autoimmune diseases, and not just the symptoms, without suppressing the entire immune system and generating unwanted side effects.
- The PantId® is a platform technology that is modular, with interchangeable components, that allow specific targeting of multiple autoimmune diseases.
Orpheus is currently developing three PantIds® that target autoimmunity caused by cancer immunotherapeutics, called checkpoint inhibitors.
- A subset of PantIds® are being developed as broad-acting immunomodulators to mitigate autoimmune disease severity in a process called "tolerogenesis."